We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

General Practice Quality Assurance Project. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00319813
First Posted: April 27, 2006
Last Update Posted: April 16, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Boehringer Ingelheim
  Purpose
A Cross sectional observational Quality Assurance Project in General Practice to COPD Diagnosis and Treatment

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive Behavioral: Education Phase 4

Study Type: Observational
Official Title: General Practice Quality Assurance Project. COPD Diagnosis and Treatment

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • To optimise the diagnosis and treatment of COPD via a quality assurance project
  • Increase the knowledge and use of diagnostic tools and treatment amongst PCPs
  • To focus on implementation of national guidelines for diagnosis and treatment of COPD

Estimated Enrollment: 8000
Estimated Study Completion Date: September 2007
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • COPD patients over 35 years of age
  • More than two annual renewals with the following group of inhalation preparations: Anticholinergic, beta-2 antagonists, steroids or a combination of these

Exclusion Criteria:

  • Asthma
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00319813


Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Study Coordinator B.I. Denmark A/S
  More Information

ClinicalTrials.gov Identifier: NCT00319813     History of Changes
Obsolete Identifiers: NCT00479869
Other Study ID Numbers: 205.376
First Submitted: April 20, 2006
First Posted: April 27, 2006
Last Update Posted: April 16, 2008
Last Verified: April 2008

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Chronic Disease
Respiratory Tract Diseases
Lung Diseases, Obstructive
Disease Attributes
Pathologic Processes